For those of you who would like to take advantage of our Luck O' the Irish SALE but prefer not to make payments online, you are welcome to send us a check or money order in the amount of $114.12 for a 3-year AD-FREE Premium Service Bundle or $190.20 for a 5-year Bundle. Make checks or money orders payable in US funds to "Investor Village" and send to: Investor Village, P.O. Box 2958, Marrero, LA 70073.
As many of you know, we operate on the honor system around here. So, in closing out our Luck O' the Irish SALE, we wanted to advise those of you who plan to pay by check or money order that you can send a PM to Admin informing us of your intention. We will then upgrade your account for 7 days, allowing you to enjoy our ad-free premium service now and giving you a reasonable amount of time to get your payment in.
That graph looks great especially for PFE's TYK2 drug. That is a new class of drug which appears to outperform their Jak3 inhibitor, PF-06651600. The TYK2/JAK1 inhibitor had a 49.5-point reduction on SALT while the JAK3 scored had a smaller33.6-point reduction. Both had great P scores. The TYK arm did have a couple of rhabdomylosis AEs which might be the reason PFE chose to advance the JAK drug which looks to be the weaker AA drug. The maintenance dose on the TYK2 was 50% of starting dose while the JAK was able to reduce it to 1/4 in the maintenance. That is something that CNCE still needs to figure out with 543. The PFE scoring is different from the Ruxo so it is hard to compare. I hate stats so I'll leave that one alone. I think pictures will tell the story in AA. I've seen 1 of a young boy treated in the study and it did look impressive, but I want to see the other responders.